Fertility Market in the US 2016-2020

  • ID: 3616202
  • Report
  • Region: United States
  • 63 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • CooperSurgical
  • Ferring Pharmaceuticals
  • Invo Bioscience
  • Meditex
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

About Fertility

Couples with fertility issues are unable to conceive even after regular unprotected coitus (six months if the woman is over age 35). Female or male infertility factors account for one-third of the cases, where a couple is unable to conceive. In the rest of the cases, the cause is either unknown or a combination of both male and female infertility factors.

In males, low sperm production, abnormal sperm function, or blockages that prevent the delivery of sperm can lead to infertility. In females, hormonal changes, fallopian tube damage, endometriosis, and cervical abnormalities can lead to infertility. Diagnosing the cause of infertility can be difficult but people with fertility issues have many treatment options depending on the underlying problem.

The analysts forecast the fertility services market in the US to grow at a CAGR of 4.07% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the fertility treatment market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of fertility drugs and the use of assisted reproductive technology (ART).

The market is divided into the following segments based on treatment type:
- ART
- Infertility drugs

The report, Fertility Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Cellcura
- CooperSurgical
- Intramed
- Ferring Pharmaceuticals
- Merck

Other prominent vendors
- Abbott Laboratories
- AbbVie
- Actavis
- Apricus Biosciences
- AstraZeneca
- Auxogyn
- Bristol-Myers Squibb
- Elelixis Diagnostics
- Eli Lilly
- EMD Serono
- IKS International
- In Vitro Care
- Invo Bioscience
- Irvine Scientific
- IVFtech Aps
- Life Global
- Medical Electronic Systems
- Meditex
- Novartis
- Ovascience
- Pantec Biosolutions
- Pfizer
- Sanofi
- Vivus
- Xytex Cryo International

Market drivers
- Emergence of ART and acceptance of same-sex marriage
- For a full, detailed list, view the full report

Market challenges
- High cost of fertility treatment
- For a full, detailed list, view the full report

Market trends
- Increase in M&A
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • CooperSurgical
  • Ferring Pharmaceuticals
  • Invo Bioscience
  • Meditex
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Regulatory scenario in the US

PART 06: Market landscape
  • Market overview
  • Five forces analysis
PART 07: Infertility: An overview
  • Etiology
  • Etiology: Female infertility
  • Signs and symptoms
  • Tests and diagnosis
  • Treatment
PART 08: Stages of fertility treatment

PART 09: Cost analysis of ART
  • Direct cost
  • Indirect cost
PART 10: Market segmentation by type
  • Infertility drugs
  • Fertility drugs market in US
  • ART
  • ART market in US
PART 11: Market drivers
  • Emergence of ART and acceptance of same-sex marriage
  • Increasing success rate of infertility treatment
  • Increase in infertility complications
PART 12: Impact of drivers

PART 13: Market challenges
  • High cost of fertility treatment
  • Complications of fertility services
  • Limited reimbursement
  • Minimal regulations
PART 14: Impact of drivers and challenges

PART 15: Market trends
  • Increase in M&A
  • Rise in R&D
  • Establishment of new fertility clinics
PART 16: Vendor landscape
  • Competitive scenario
  • Key news
  • Mergers and acquisitions
  • Licensing and collaborations
  • Market share analysis
  • Other prominent vendors
PART 17: Appendix
  • List of abbreviations
PART 18: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Number of ART procedures in US 2002-2013
Exhibit 03: Number of ART procedures in the US by fresh embryo from non-donor oocytes
Exhibit 04: Number of ART procedures in the US by thawed embryos from non-donor oocytes
Exhibit 05: Fertility services market in US 2015-2020 ($ billions)
Exhibit 06: Five forces analysis
Exhibit 07: Types of infertility
Exhibit 08: Causes of male infertility
Exhibit 09: Causes of female infertility
Exhibit 10: Stages of fertility treatment
Exhibit 11: Segmentation of fertility services market in US by treatment type
Exhibit 12: Segmentation of fertility services market in US by treatment type 2015
Exhibit 13: Fertility drugs market in US 2015-2020 ($ billions)
Exhibit 14: Types of ART
Exhibit 15: IVF procedure
Exhibit 16: Success rate of IVF
Exhibit 17: Infertility rate in US by sex 2010
Exhibit 18: Infertility rate in US by age 2002 and 2010
Exhibit 19: Different categories of ART in US
Exhibit 20: Comparison of fresh and frozen ART cycle
Exhibit 21: ART market in US 2015-2020 ($ billions)
Exhibit 22: ART procedures and number of infants born in US 2002-2011 (thousands)
Exhibit 23: Same-sex married couples in US 2008-2013 (thousands)
Exhibit 24: Infertility by reproductive group in US
Exhibit 25: Adult Americans with obesity 2012
Exhibit 26: Adult Americans with obesity 2030
Exhibit 27: Impact of drivers
Exhibit 28: Average cost of fertility services in US
Exhibit 29: States that require people to have insurance coverage for fertility services
Exhibit 30: Impact of drivers and challenges
Exhibit 31: Recent M&A
Exhibit 32: Number of fertility clinics in US 2010-2014
Exhibit 33: CellCura: Key takeaways
Exhibit 34: CooperSurgical: Business segmentation by revenue 2014
Exhibit 35: IntegraMed: Key takeaways
Exhibit 36: Ferring Pharmaceuticals: Key takeaways
Exhibit 37: Merck: Business segmentation by revenue 2014
Exhibit 38: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 39: Merck: Geographical segmentation by revenue 2014
Exhibit 40: Merck: Key drivers in fertility services sector
Exhibit 41: Merck: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • CooperSurgical
  • Ferring Pharmaceuticals
  • Invo Bioscience
  • Meditex
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

New Report Released: - Fertility Market in the US 2016-2020

The author of the report recognizes the following companies as the key players in the Fertility Market in the US: Cellcura, CooperSurgical, Intramed, Ferring Pharmaceuticals and Merck

Other Prominent Vendors in the market are: Abbott Laboratories, AbbVie, Actavis, Apricus Biosciences, AstraZeneca, Auxogyn, Bristol-Myers Squibb, Elelixis Diagnostics, Eli Lilly, EMD Serono, IKS International, In Vitro Care, Invo Bioscience, Irvine Scientific, IVFtech Aps, Life Global, Medical Electronic Systems, Meditex, Novartis, Ovascience, Pantec Biosolutions, Pfizer, Sanofi, Vivus, and Xytex Cryo International.

Commenting on the report, an analyst from the research team said: “Vendors undergo M&A to expand their geographical presence, enhance their product portfolio, and attain profit margins. M&A allows vendors to gain proprietary technologies and innovative products of the acquired company. Small vendors undergo M&A to broaden their network and expand people's access to their new products.”

According to the report, the fertility market in the US consists of fertility drugs and assisted reproductive technology (ART) services segments. Increasing fertility issues among the aging population, rising disposable income, growing adoption of fertility services by homosexual couples, and augmented support from the US federal government are some of the major factors that will impel growth in this market during the forecast period.

Further, the report states that high cost of fertility treatment hinders the market growth.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

- Cellcura
- CooperSurgical
- Intramed
- Ferring Pharmaceuticals
- Merck
- Abbott Laboratories
- AbbVie
- Actavis
- Apricus Biosciences
- AstraZeneca
- Auxogyn
- Bristol-Myers Squibb
- Elelixis Diagnostics
- Eli Lilly
- EMD Serono
- IKS International
- In Vitro Care
- Invo Bioscience
- Irvine Scientific
- IVFtech Aps
- Life Global
- Medical Electronic Systems
- Meditex
- Novartis
- Ovascience
- Pantec Biosolutions
- Pfizer
- Sanofi
- Vivus
- Xytex Cryo International.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll